Massive Gains: 10 Stocks Investors Can’t Stop Buying

Page 9 of 9

1. PepGen Inc. (NASDAQ:PEPG)

Shares of PepGen soared by 121.05 percent on Thursday to end at $5.88 apiece as investors cheered stellar results from its clinical trial of an experimental drug to treat myotonic dystrophy type 1 (DM1).

In a statement, PepGen Inc. (NASDAQ:PEPG) said it saw a 53.7 percent correction in the key genetic error that drives the disease in patients taking 15 mg/kg of the drug candidate called PGN-EDODM1.

It was higher than any previously reported splicing correction in DM1 patients.

“We are delighted to report that the … clinical study achieved all of its key objectives, including unprecedented splicing correction following a single dose of PGN-EDODM1 at 15 mg/kg,” said Paul Streck, EVP for research and development.

“Since mis-splicing is the underlying cause of DM1, we believe high levels of splicing correction have the potential to reverse the underlying molecular defects, and produce functional improvements in multiple outcome measures, including myotonia and muscle weakness, in repeat dose studies.”

Following the results, PepGen Inc. (NASDAQ:PEPG) kicked off a $100 million public offering, covering the sale of 31.25 million shares at a price of $3.20 apiece.

PepGen Inc. (NASDAQ:PEPG) said it plans to use the proceeds to fund its ongoing research and clinical development efforts, including the DM1 clinical trials, while the balance will be allocated for other general corporate purposes.

While we acknowledge the potential of PEPG to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PEPG and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.

Page 9 of 9